We are live on ! Find out more
CP

Caligan Partners Portfolio holdings

AUM $2.13B
1-Year Est. Return 758.65%
This Fund
S&P 500
This Quarter Est. Return
+57.99%
1 Year Est. Return
+758.65%
3 Year Est. Return
+2,628.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.13B
AUM Growth
+$623M
Cap. Flow
+$59.8M
Cap. Flow %
2.81%
Top 10 Hldgs %
80.89%
Holding
33
New
5
Increased
11
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$45.1M
2
IMCR icon
Immunocore
IMCR
+$40.9M
3
VRDN icon
Viridian Therapeutics
VRDN
+$35.3M
4
AURA icon
Aura Biosciences
AURA
+$29.1M
5
AVTX icon
Avalo Therapeutics
AVTX
+$24.2M

Top Sells

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$75.1M
2
SYRE icon
Spyre Therapeutics
SYRE
+$44.3M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$27.9M
4
MBX
MBX Biosciences
MBX
+$22.7M
5
MAZE
Maze Therapeutics
MAZE
+$18.4M

Sector Composition

Rank Sector Weight
1 Healthcare 97.51%
2 Miscellaneous 2.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
1
Liquidia Corp
LQDA
$6.14B
$647M 30.45%
8,118,892
– –
RVMD icon
2
Revolution Medicines
RVMD
$45.2B
$367M 17.28%
1,961,795
+308,987
+19% +$45.1M
ABVX
3
Abivax
ABVX
$9.95B
$208M 9.77%
1,557,924
+96,000
+7% +$10.9M
PCVX icon
4
Vaxcyte
PCVX
$9.1B
$127M 5.99%
2,188,636
+127,917
+6% +$6.95M
EXEL icon
5
Exelixis
EXEL
$14.7B
$84.5M 3.98%
1,553,262
– –
TNGX icon
6
Tango Therapeutics
TNGX
$3.84B
$78.2M 3.68%
2,500,103
+91,305
+4% +$2.26M
AVTX icon
7
Avalo Therapeutics
AVTX
$1.02B
$58.5M 2.75%
3,163,866
+1,528,843
+94% +$24.2M
XENE icon
8
Xenon Pharmaceuticals
XENE
$5.85B
$53.7M 2.53%
889,944
-503,083
-36% -$27.9M
ADMA icon
9
ADMA Biologics
ADMA
$2.15B
$47.9M 2.25%
5,725,007
+968,496
+20% +$8.83M
RVMD icon
10
CALL
Revolution Medicines
RVMD
$45.2B
$47.2M 2.22%
251,800
+22,900
+10% +$3.34M
LBRX
11
LB Pharmaceuticals
LBRX
$1.53B
$46.7M 2.2%
1,438,070
– –
IMCR icon
12
Immunocore
IMCR
$1.93B
$43.9M 2.06%
+1,381,317
New +$40.9M
VRDN icon
13
Viridian Therapeutics
VRDN
$2.6B
$40.3M 1.9%
+2,193,981
New +$35.3M
VOR icon
14
Vor Biopharma
VOR
$1.43B
$35.4M 1.67%
1,925,066
– –
SABS icon
15
SAB Biotherapeutics
SABS
$338M
$31.1M 1.46%
7,967,207
– –
IVA
16
Inventiva
IVA
$1.14B
$30.9M 1.45%
8,163,191
+3,188,285
+64% +$15.3M
AURA icon
17
Aura Biosciences
AURA
$764M
$30.5M 1.44%
4,298,248
+4,068,384
+1,770% +$29.1M
TYRA icon
18
Tyra Biosciences
TYRA
$1.48B
$25.8M 1.21%
806,986
-469,982
-37% -$15.5M
IRD
19
Opus Genetics
IRD
$383M
$25M 1.18%
6,077,084
+2,056
+0% +$9.59K
ANIK icon
20
Anika Therapeutics
ANIK
$281M
$21M 0.99%
1,435,130
– –
SGMT icon
21
Sagimet Biosciences
SGMT
$679M
$19.3M 0.91%
+2,500,000
New +$17M
ARTV
22
Artiva Biotherapeutics
ARTV
$544M
$16.8M 0.79%
+1,736,111
New +$15.8M
FTH
23
Faeth Therapeutics
FTH
$1.01B
$15.7M 0.74%
629,467
+503,465
+400% +$11.6M
MBX
24
MBX Biosciences
MBX
$2.96B
$11M 0.52%
200,000
-648,590
-76% -$22.7M
VRCA icon
25
Verrica Pharmaceuticals
VRCA
$92.1M
$5.65M 0.27%
923,910
– –
1
2

Similar funds

MWA
Midland Wealth Advisors Effingham, Illinois $2.13B AUM 17.72% 1-Year Est. Return
CWP
Cyndeo Wealth Partners St. Petersburg, Florida $2.12B AUM 24.61% 1-Year Est. Return
SP
Stairway Partners Chicago, Illinois $2.12B AUM 17.37% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $2.12B AUM 32.36% 1-Year Est. Return
GC
Gobi Capital San Francisco, California $2.13B AUM 6.1% 1-Year Est. Return
BP
BBR Partners New York $2.13B AUM 21.87% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $2.12B AUM 67.44% 1-Year Est. Return
NONA
Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return

Caligan Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Caligan Partners held 33 positions worth $2.13B, up 41% from $1.5B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Caligan Partners's Q2 2026 filing shows 5 new, 11 increased, 3 reduced and 5 closed positions. Its largest new stake was Immunocore: 1,381,317 shares worth $43.9M. The largest sale was Mineralys Therapeutics, an estimated $75.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Miscellaneous.

  • Caligan Partners's largest Q2 2026 buy was Immunocore: 1,381,317 shares worth $43.9M.
  • Caligan Partners added most to Revolution Medicines in Q2 2026, an estimated $45.1M increase.
  • Caligan Partners's biggest Q2 2026 reduction was Xenon Pharmaceuticals, cutting an estimated $27.9M.
  • Caligan Partners fully exited Mineralys Therapeutics in Q2 2026, selling an estimated $75.1M.
  • Caligan Partners's ten largest holdings make up 81% of its $2.13B portfolio in Q2 2026.
  • Caligan Partners opened 5 new positions and closed 5 in Q2 2026.
  • Caligan Partners's portfolio value rose 41% quarter-over-quarter to $2.13B.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.